3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
12
Plasma cell
4
Other
4
Genitourinary
4
Gastrointestinal
4
Thoracic
3
Lymphoid
3
Head & Neck
3
Other hematologic neoplasm
2
Tumor-Agnostic
1
Sarcoma
1
Other neoplasm
1
Myeloid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Liposarcoma
1
Interventions
Radiotherapy
144
Doxorubicin
112
Temozolomide
110
Cyclophosphamide
110
Filgrastim
79
Ifosfamide
70
Imatinib Mesylate
69
Etoposide
69
Bevacizumab
55
Vincristine
51
Gemcitabine
50
Peripheral Blood Stem Cell Transplantation
47
Irinotecan
43
Methotrexate
39
Cisplatin
36
Carboplatin
36
Radiation
35
fludarabine phosphate
34
Busulfan
34
pazopanib
32
Sirolimus
30
Melphalan
30
Trabectedin
29
Docetaxel
27
Chemotherapy, Adjuvant
27
Cyclosporine
25
Carmustine
25
sargramostim
24
Surgical Procedures, Operative
23
Sunitinib
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Sugars
×
Sarcoma
×
Clear all
NCT02606461
2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3
Completed
342 enrolled
36 charts